Risperidone in the treatment of psychotic patients with opiate abuse and dependence;Risperidona en el tratamiento de pacientes psicóticos con abuso y dependencia de opiáceos

Actas Espanolas de Psiquiatria

Volumn 29, Issue 6, 2001, Pages 380-385

  Casas, M ^a,d   Gutierrez M ^b   Gibert, J ^e   Bobes, J ^e   Roncero, C ^e   Octavio, I ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Janssen Research Foundation   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e NONE

Author keywords

Opiate abuse; Psychotic disorder; Risperidone; Treatment

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HUMAN; IATROGENIC DISEASE; MALE; OPIATE ADDICTION; PSYCHOSIS; RATING SCALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRIEF PSYCHIATRIC RATING SCALE; DRUG TOLERANCE; ENGLISH ABSTRACT; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; OPIOID-RELATED DISORDERS; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 0035542905     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Limbeek JV, Wouters L, Kaplan CD, Geerlings PJ, Alem W. Prevalence of psychopatology in drug-addicted Dutch. J Subst Abuse Treat 1992;9:43-52.
2. Shaner A, Khalsa M, Roberts L, Wilkins J, Anglin D, Hsieh S. Unrecogsigned cocaine used among schizophrenic patients. Am J Psychiatry 1993;150:758-62.
3. Batel P. Addiction and schizophrenia. Eur Psychiatry 2000;15:115-22.
4. Laudet AB, Magura S, Vogel HS, Knight E. Recovery challenges among dually diagnosed individuals. J Subst Abuse Treat 2000;18:321-9.
5. Gearon JS, Bellack AS. Sex differences in illness presentation, course and level of functioning in substance-abusing schizophrenia patients. Schizophr Res 2000;43:65-70.
6. Scheller-Gilkey G, Lewine RJ, Claudle J, Brown FW. Schizophrenia, substance use, and brain morphology. Schizophr Res 1999;35:113-20.
7. Rabinowitz J, Bromet EJ, Lavalle J, Carsson G, Kovasznay B, Schwartz JE. Prevalence, severity of substance use disorders and outset of psychosis in first-admission psychotic patients. Psychol Med 1998;15:1411-9.
8. Liraud F, Verdoux H. Which temperamental characteristics are associated with substance abuse use in subjects with psychotic and mood disorders? Psychiatry Res 2000;93:63-72.
9. Casas M, Pérez de los Cobos J, Salazar I, Tejero A. Las conductas de automedicación en drogodependencias. En: Casas M, coord. Trastornos psíquicos en las toxicomanías. Ediciones en Neurociencias 1992:291-304.
10. Salokangas RK, Saarijarvi S, Taiminen T, Lehto H, Niemi H, Ahola V. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997;23:55-60.
11. Nair NPV, and the Risperidone Study Group. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol 1998;18:103-10.
12. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
13. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
14. Peuskens J. on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
15. Chouinard G, Arnott W. Clinical review of risperidone. Am J Psychiatry 1993;38(Supl 3):S89-95.
16. Marder SR, Meibach RD. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35-
17. Editorial. Risperidone in schizophrenia. BMJ 1994; 308:1311-2.
18. Remington G. Clinical considerations in the use of risperidone. Can J Psychiatry 1993;38(Supl 3):S96-100.
19. Livington MG. Risperidone. Lancet 1994;343:457-60.
20. Directrices para la realización de estudios de farmacovigilancia. Circular n° 18/90 de 21 de noviembre de la Dirección General de Farmacia y Productos Sanitarios. Ministerio de Sanidad y Consumo; 1990.
21. Casas M, Prat G, Santís R. Trastornos por dependencia de sustancias psicotrópas. En: Cervilla JA, García-Ribera C. Fundamentos biológicos en psiquiatría. Barcelona: Masson; 2000. p. 269-81.